Your browser doesn't support javascript.
loading
Hormone therapy for postmenopausal osteoporosis management.
Jiang, X; Kagan, R.
Affiliation
  • Jiang X; Department of Obstetrics and Gynecology, The Reading Hospital of Tower Health System, Reading, PA, USA.
  • Kagan R; Departments of Obstetrics and Gynecology, Sydney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA.
Climacteric ; 25(1): 50-55, 2022 02.
Article in En | MEDLINE | ID: mdl-34402365
ABSTRACT
Menopausal hormone therapy (MHT) has been used for prevention and treatment of postmenopausal osteoporosis for several decades. However, public concerns were raised over the safety of MHT after the initial report was published in 2002 by the Women's Health Initiative. We conducted a historical review on this subject, primarily focusing on level I evidence from randomized controlled trials, systematic reviews and meta-analyses, and summarized high-quality evidence on the efficacy and safety of MHT in management of postmenopausal osteoporosis. Clinical issues were also discussed on MHT initiation, identification of treatment candidates and treatment duration, as well as discontinuation of MHT.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Osteoporosis, Postmenopausal Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans Language: En Journal: Climacteric Journal subject: GINECOLOGIA Year: 2022 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Osteoporosis, Postmenopausal Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans Language: En Journal: Climacteric Journal subject: GINECOLOGIA Year: 2022 Document type: Article Affiliation country: United States